Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has entered into an agreement with DNA Bioservices Pty. Ltd. to provide paternity testing services to China.
With reference to the clinical trial currently underway for HeartWare's (ASX: HTW) HVAD left ventricular assist device, Mr McConchie commented:
HeartWare (ASX: HTW) in accordance with ASX Listing Rule 3.13.3 provides a copy of the presentations which are to be delivered today at the Company's Annual General Meeting.
HeartWare (ASX: HTW) is pleased to announce that it has received regulatory approval from the Medicines and Healthcare Products Regulatory Agency ("MHRA") to commence implants of its HVAD circulatory assist device in the United Kingdom.
HeartWare Limited (ASX: HTW) announced to shareholders the Share Purchase Plan dated 19 May 2006 (Plan). The Plan allows shareholders to purchase up to A$5,000 worth of ordinary shares in HeartWare Limited (Heartware or the Company) at A$1.10 per share, which is an issue price discounted to the market price of HeartWare shares on the Australian Stock Exchange (ASX) and free of brokerage or transaction costs.
HeartWare Limited (ASX: HTW) is pleased to announce that it has received commitments for $32.5 million from institutional and sophisticated investors in Australia and the United States.
HeartWare is pleased to announce the appointment of Mr Dozier Rowe as Chief Operating Officer, based at HeartWare's operations centre in Miramar, Florida.
